vs

Side-by-side financial comparison of AC Immune SA (ACIU) and NOVARTIS AG (NVS). Click either name above to swap in a different company.

AC Immune SA is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics and diagnostic solutions for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and rare tauopathies. It operates globally, partners with leading pharmaceutical enterprises, and prioritizes addressing unmet medical needs in neurological care segments.

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACIU
ACIU
NVS
NVS
Q2 25
$1.4M
Q2 24
$755.7K
Q3 22
$4.3M
Net Profit
ACIU
ACIU
NVS
NVS
Q2 25
$-23.3M
Q2 24
$-25.0M
Q3 22
$-14.9M
Operating Margin
ACIU
ACIU
NVS
NVS
Q2 25
-1484.5%
Q2 24
-3051.1%
Q3 22
-342.2%
Net Margin
ACIU
ACIU
NVS
NVS
Q2 25
-1622.4%
Q2 24
-3313.0%
Q3 22
-343.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons